Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-7684A versus pembrolizumab monotherapy for first-line PD-L1-positive metastatic non-small cell lung cancer
2020-004049-35Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Feb 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing MK-7684A with Pembrolizumab monotherapy (2 arms). Primary endpoints: Progression-free survival and Overall survival. Started Feb 2021; status: active.
02
Drugs
vibostolimab + pembrolizumabpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2020-004049-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004049-35.